Development of monoclonal antibodies against prM of Dengue virus 4

Andrade, Adriana de Souza; Campos, Gubio Soares; Costa, Lilia Ferreira Moura; Monte-Alegre, Adriano; Sardi, Silvia Inês.
Rev. Ciênc. Méd. Biol. (Impr.) ; 21(1): 40-45, maio 05,2022. fig
Artículo en Portugués | LILACS | ID: biblio-1370563

Documentos relacionados

  1. Immune response to dengue virus and prospects for a vaccine.
  2. Viperin is anti-viral <i>in vitro</i> but is dispensable for restricting dengue virus replication or induction of innate and inflammatory responses <i>in vivo</i>.
  3. Development and characterization of serotype-specific monoclonal antibodies against the dengue virus-4 (DENV-4) non-structural protein (NS1).
  4. Paradoxical Role of Dengue Virus Envelope Protein Domain III Antibodies in Dengue Virus Infection.
  5. Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.
  6. Dengue Virus Immunity Increases Zika Virus-Induced Damage during Pregnancy.
  7. Combination of Modified NS1 and NS3 as a Novel Vaccine Strategy against Dengue Virus Infection.
  8. Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope.
  9. The inflammasome pathway is activated by dengue virus non-structural protein 1 and is protective during dengue virus infection.
  10. Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans.